摘要 |
<p>Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine formulations are disclosed which are useful in prophylactic or therapeutic vaccine and/or gene therapy-based applications. These adjuvants comprise a block copolymer and a cationic surfactant component. The inclusion of a cationic surfactant results in an increased percentage of polynucleotide that is physically associated with the adjuvant in vitro, resulting in enhanced in vivo immune responses to polynucleotide vaccines.</p> |